Table 3 The laboratory findings, complications, treatment and clinical outcome in the older patients

Age (years)

66.0 (63.0–69.0)

79.0 (76.0–82.0)

Male

96 (44.4%)

57 (62.6%)

 Any

143 (66.2%)

79 (86.8%)

 Hypertension

96 (44.4%)

62 (68.1%)

 Diabetes

37 (17.1%)

15 (16.5%)

 CAD

27 (12.5%)

23 (25.3%)

 Cerebral infarction

8 (3.7%)

13 (14.3%)

 Cancer

6 (2.8%)

3 (3.3%)

 CKD

3 (1.4%)

4 (4.4%)

 COPD

3 (1.4%)

4 (4.4%)

 White blood cells (10⁹/L)

5.72 (4.34–7.39)

5.96 (4.74–8.12)

 Neutrophils (10⁹/L)

3.70 (2.54–5.47)

4.30 (3.37–6.54)

 Lymphocytes (10⁹/L)

1.18 (0.73–1.68)

0.85 (0.59–1.29)

  < 0.8

58 (26.9%)

43 (47.3%)

 Hemoglobin (g/L)

121.0 (112.0–131.0)

121.0 (109.0–133.0)

 Platelet (10⁹/L)

213.0 (165.3–269.5)

197.0 (134.0–242.0)

  < 100

10 (4.6%)

9 (9.9%)

 CRP (mg/L)

18.90 (1.37–73.09)

53.55 (12.28–73.03)

 ALT (U/L)

24.0 (16.0–35.8)

23.0 (16.0–39.0)

 AST (U/L)

25.0 (18.0–35.8)

30.0 (21.0–48.0)

 Albumin (g/L)

37.1 (33.6–40.0)

35.0 (32.0–37.7)

  < 30

11 (5.1%)

7 (7.7%)

 Urea nitrogen (mmol/L)

5.10 (4.00–6.51)

7.70 (4.80–11.31)

 Creatinine (μmol/L)

60.0 (50.0–70.0)

68.0 (57.0–100.0)

 Blood glucose (mmol/L)

5.80 (5.06–7.74)

5.79 (4.90–7.01)

 Creatine kinase (U/L)

59.0 (42.0–86.5)

62.0 (42.5–150.0)

 LDH (U/L)

252.0 (200.0–346.0)

289.0 (230.0–452.0)

 CK-MB (ng/mL)

1.12 (0.83–1.63)

2.27 (1.32–4.43)

 cTnI (ng/mL)

0.006 (0.006–0.014)

0.027 (0.010–0.193)

 ARDS

56 (25.9%)

32 (35.2%)

 Acute cardiac injury

23/215 (10.7%)

43/91 (47.3%)

  With history of cardiovascular disease

19/108 (17.6%)

37/70 (52.9%)

  Without history of cardiovascular disease

4/107 (3.7%)

6/21 (28.6%)

 Heart failure (elevated BNP)

21/185 (11.4%)

18/84 (21.4%)

 New or worsening arrhythmia

54 (25.0%)

17 (18.7%)

 Acute liver injury

20 (9.3%)

15 (16.5%)

 Acute kidney injury

4 (1.9%)

9 (9.9%)

 Skeletal muscle injury

9/204 (4.4%)

11/81 (13.6%)

 Discharge

191 (88.4%)

59 (64.8%)

 Death

25 (11.6%)

32 (35.2%)